Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel
- PMID: 8761362
- PMCID: PMC2074676
- DOI: 10.1038/bjc.1996.393
Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel
Abstract
A panel of doxorubicin-resistant sublines of the human small-cell lung carcinoma cell line GLC4 displays decreasing DNA topoisomerase II alpha (TopoII alpha) mRNA levels with increasing resistance. In the present study we describe how this decrease may be regulated. No significant differences in TopoII alpha mRNA stability or gene arrangement were found, using mRNA slot-blotting and Southern blotting, in the most resistant cell line compared with the parental cell line. To investigate if TopoII alpha gene copy loss contributed to the mRNA decrease, fluorescence in situ hybridisation using a TopoII alpha-specific probe was performed. During doxorubicin resistance development, the composition of the population in each cell line shifted with increasing resistance, from a population in which most cells contain three TopoII alpha gene copies (GLC4) to a population in which most cells contain only two copies. A partial revertant of the most resistant cell line displayed a shift back to the original situation. We conclude that the TopoII alpha gene copy number decrease per cell line is in good agreement with the decreased TopoII alpha mRNA and protein levels, and TopoII activity levels in these cell lines which were described previously.
Similar articles
-
Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4.Br J Cancer. 1996 Dec;74(12):1869-76. doi: 10.1038/bjc.1996.647. Br J Cancer. 1996. PMID: 8980384 Free PMC article.
-
Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay.Lab Invest. 1994 Jul;71(1):61-6. Lab Invest. 1994. PMID: 8041119
-
Enhanced sensitivity to tumor necrosis factor-alpha in doxorubicin-resistant tumor cell lines due to down-regulated c-erbB2.Int J Cancer. 1998 Jul 3;77(1):101-6. doi: 10.1002/(sici)1097-0215(19980703)77:1<101::aid-ijc16>3.0.co;2-h. Int J Cancer. 1998. PMID: 9639400
-
Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance.Int J Cancer. 1995 May 4;61(3):375-80. doi: 10.1002/ijc.2910610317. Int J Cancer. 1995. PMID: 7729950
-
Topoisomerase expression in cancer cell lines and clinical samples.Cancer Chemother Pharmacol. 1994;34 Suppl:S32-40. doi: 10.1007/BF00684861. Cancer Chemother Pharmacol. 1994. PMID: 8070025 Review.
Cited by
-
Biological indicators of chemoresistance: an ex vivo analysis of γH2AX and p53 expression in feline injection-site sarcomas.Cancer Cell Int. 2018 Nov 22;18:192. doi: 10.1186/s12935-018-0690-0. eCollection 2018. Cancer Cell Int. 2018. PMID: 30498397 Free PMC article.
-
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.Breast Cancer Res Treat. 2024 Jun;205(2):267-279. doi: 10.1007/s10549-024-07285-y. Epub 2024 Mar 7. Breast Cancer Res Treat. 2024. PMID: 38453781 Free PMC article. Clinical Trial.
-
HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics.Breast Care (Basel). 2012 Dec;7(6):465-70. doi: 10.1159/000345467. Breast Care (Basel). 2012. PMID: 24715828 Free PMC article. Review.
-
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.J Clin Oncol. 2011 Mar 1;29(7):859-67. doi: 10.1200/JCO.2009.27.5644. Epub 2010 Dec 28. J Clin Oncol. 2011. PMID: 21189395 Free PMC article. Clinical Trial.
-
Use of a rapid throughput in vivo screen to investigate inhibitors of eukaryotic topoisomerase II enzymes.Antimicrob Agents Chemother. 1998 Apr;42(4):889-94. doi: 10.1128/AAC.42.4.889. Antimicrob Agents Chemother. 1998. PMID: 9559802 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical